TheranosticTrials.org

Clinical Trial · NCT07767630

Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma

Overview

Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma

Sponsor

Sohag University

Phase

Early Phase 1

Contacts

Xiaoao WU, PHD (CONTACT)

allenfire511@163.com

+86 189 8060 2715

Rong TIAN, MD (PRINCIPAL_INVESTIGATOR)

Rong TIAN, MD (CONTACT)

rongtiannuclear@126.com

+86 189 8060 1586

ClinicalTrials.gov

NCT07767630

Drug / Compound

MABG

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Lansky performance status ≥ 50%.
  • Adequate organ function and hematologic parameters.
  • Patients diagnosed with MIBG avid lesions, high-risk neuroblastoma per the Revised International Neuroblastoma Response Criteria (Revised INRC), with refractory, relapsed, or progressive disease.
  • All measurable soft tissue lesions must be MIBG-avid.

Exclusion

  • Renal Insufficiency.
  • Autologous stem cell transplant \<12 weeks, or Allogeneic stem cell transplant \<4 months (patients \>4 months post-transplant must be free of active GVHD).
  • Antibody-based immunotherapy within fewer than 5 half-lives or 30 days (whichever is shorter), or who have not yet recovered from adverse effects of any biologic therapy.